The University of Pennsylvania Cancer Center is the largest and oldest institute of the University of Pennsylvania. Its mission is to facilitate multi-disciplinary, interdepartmental cancer research, education and patient care. Its mission is to facilitate multi-disciplinary, interdepartmental cancer research, education and Glick, MD, has directed the Cancer Center for 14 years. The Cancer Center's three Divisions (Fundamental Research, Clinical Research, and Population Science and Cancer Control) are comprised of inter-disciplinary Research Programs in: Immunobiology, Tumor Biology, Virology, Clinical Investigations, Melanoma, Pediatric Oncology, Radiation Biology, Gene Therapy in Cancer, Stem Cell Biology and Therapeutics, Neuro-Oncology, Breast Cancer, and Behavioral Sciences and Health Services Research Programs as well as a Developing Chemoprevention Program. This application includes 16 Shared Resources. The Flow Cytometry and Cell Sorting Facility, Nucleic Acid Facility, Melanoma Core, Biostatistics Unit and Clinical Research Unit are among the oldest NCI-funded cores. A wide range of research seminars and interdisciplinary laboratory space are used to facilitate member interaction and collaboration. Developmental Funds are critical to supporting faculty recruitment, innovative pilot projects that have the potential for peer-reviewed funding, translational research initiatives and Shared Resources. The development and expansion of Research Programs and Shared Resources, along with the recruitment of new faculty and acquisition of additional research space have all contributed to helping the Cancer Center reach its current level of excellence. A comprehensive, interactive strategic planning process has been instrumental in identifying future directions in cancer research, Research Programs and Shared Resources and allocation of resources. The Cancer Center continues to meet Comprehensiveness guidelines and was last fully approved for the maximum five-year period in 1995. Cancer Center members have $99.2 million in research and training in total costs (direct and indirect), of which $91 million is peer-reviewed and $35.4 million is from the National Cancer Institute.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016520-28S1
Application #
6765397
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1978-12-01
Project End
2004-11-30
Budget Start
2002-12-01
Budget End
2003-11-30
Support Year
28
Fiscal Year
2003
Total Cost
$249,995
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications